Amundi Grows Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Amundi boosted its position in Repligen Co. (NASDAQ:RGEN) by 11.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 85,863 shares of the biotechnology company’s stock after acquiring an additional 8,790 shares during the period. Amundi’s holdings in Repligen were worth $13,283,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Edgestream Partners L.P. purchased a new stake in Repligen in the 4th quarter worth approximately $1,499,000. Callan Family Office LLC purchased a new stake in Repligen in the 4th quarter worth approximately $434,000. Raymond James Financial Inc. purchased a new stake in Repligen in the 4th quarter worth approximately $52,492,000. Arizona State Retirement System boosted its holdings in shares of Repligen by 0.8% in the 4th quarter. Arizona State Retirement System now owns 15,410 shares of the biotechnology company’s stock valued at $2,218,000 after purchasing an additional 126 shares during the last quarter. Finally, Proficio Capital Partners LLC acquired a new position in shares of Repligen in the 4th quarter valued at $3,066,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on RGEN shares. Royal Bank of Canada lifted their price target on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. JPMorgan Chase & Co. lifted their price target on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, February 21st. TD Cowen started coverage on shares of Repligen in a report on Monday, February 10th. They issued a “buy” rating and a $200.00 price target on the stock. StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a report on Friday, February 21st. Finally, Canaccord Genuity Group started coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, Repligen presently has an average rating of “Moderate Buy” and a consensus price target of $181.00.

Repligen Stock Performance

Shares of RGEN stock opened at $150.62 on Friday. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $200.23. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a market capitalization of $8.44 billion, a P/E ratio of -295.33, a P/E/G ratio of 4.54 and a beta of 0.95. The company’s fifty day moving average price is $157.19 and its two-hundred day moving average price is $148.48.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. On average, research analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.